Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

PFIZER · NSE

Pfizer

₹3,858.90

▼ -0.42%

Close (EOD), as of 1 Oct 2026 · source

Not in active coverage. Cited reporting has mentioned Pfizer, the record of those mentions is below. Your interest is logged; coverage expands by demand.

Mentions in cited reporting

Pfizer India stated that it has been working with authorities for the last one month since the matter was brought to its attention.

indiatimes.comsingle-source report24 Sep 2026

Pfizer India stated that patient safety and product quality are its highest priorities.

outlookbusiness.comsingle-source report23 Sep 2026

Novartis India's board approved the acquisition of the 'Minipress' and 'Minipres' trademarks from Pfizer Inc, USA, and Pfizer Products Inc, USA, for approximately Rs 1,250 crore.

dealbusinesstoday.inthehindubusinessline.comcorroborated · 2 sources9 Sep 2026

Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for about ₹1,250 crore.

dealindiatimes.comsingle-source report7 Sep 2026

Novartis India's board has approved the acquisition of the trademarks 'Minipress' and 'Minipres' registered in India, along with certain related intellectual property rights, from Pfizer Inc, USA, and Pfizer Products Inc, USA, for a total aggregate consideration of ₹1,250 crore.

dealcnbctv18.combusinesstoday.incorroborated · 2 sources7 Sep 2026

The Trump administration has reached voluntary agreements with 17 pharmaceutical companies including Pfizer, Eli Lilly and Amgen to slash medicine prices for the government's Medicaid program and for cash payers.

indiatimes.comsingle-source report27 Aug 2026

Every claim carries its citation

This page lists where cited reporting has mentioned Pfizer. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.